https://www.bloomberg.com/news/articles/2021-05-27/china-s-sinopharm-publishes-awaited-covid-vaccine-study-details
Vaccines from China’s Sinopharm successfully contained Covid-19, according to a study published in a prestigious U.S. medical journal, the first time detailed findings from a late-stage trial of a Chinese shot have appeared in the scientific literature.
China’s Sinopharm Publishes Awaited Covid Vaccine Study Details
Published in Business and Uncategorized
More from BusinessMore posts in Business »
- Pound Sterling Price News and Forecast: GBP/USD slips despite strong UK Retail Sales as USD dominance prevails
- US Dollar climbs as trade rumors fuel market speculation
- US President Trump: We will be reasonable on tariffs
- Dow Jones dips as trade uncertainty lingers, consumer sentiment sinks
- USD/CAD holds firm as mixed trade headlines cloud USD outlook
- Research: When Leaders Express Positivity Early On, Employees Perform Better
- 7 AI Tools That Help You Build a One-Person Business — and Make Money While You Sleep
- Microsoft Created an Ad Using AI and No One Picked Up On It: ‘Saved 90% of the Time and Cost’
- This Quiet Shift Is Helping Founders Build Fierce Customer Loyalty
- Want to Boost Your Profits by Up to 95%? Focus on This Underrated Metric.
More from UncategorizedMore posts in Uncategorized »
- Pound Sterling Price News and Forecast: GBP/USD slips despite strong UK Retail Sales as USD dominance prevails
- US Dollar climbs as trade rumors fuel market speculation
- US President Trump: We will be reasonable on tariffs
- Dow Jones dips as trade uncertainty lingers, consumer sentiment sinks
- USD/CAD holds firm as mixed trade headlines cloud USD outlook
- Research: When Leaders Express Positivity Early On, Employees Perform Better
- 7 AI Tools That Help You Build a One-Person Business — and Make Money While You Sleep
- Microsoft Created an Ad Using AI and No One Picked Up On It: ‘Saved 90% of the Time and Cost’
- This Quiet Shift Is Helping Founders Build Fierce Customer Loyalty
- Want to Boost Your Profits by Up to 95%? Focus on This Underrated Metric.